AUTHORS
Omer Jamy, MD, Joshua Knapp, BS2, Kendall Diebold, CNP, MSN3, Radwan Darwish4, Na Xie, PhD5, V K Chaithanya Manam6, Gracie Jack7, Aditi Sharma, MD8, Razan Mohty, MD9, Manuel Ricardo Espinoza-Gutarra, MD10, Pankit Vachhani, MD11, Zaid Al-Kadhimi, MD12, Kimo Bachiashvili, MD13, Sravanti Rangaraju, MD14, Jorge Cortes, MD15, Ravi Bhatia, MD16
AFFILIATIONS
1 The University of Alabama at Birmingham, Birmingham, Alabama, United States
2 The University of Alabama at Birmingham, Birmingham, Alabama, United States
3 The University of Alabama at Birmingham, Birmingham, Alabama, United States
4 The University of Alabama at Birmingham, Birmingham, Alabama, United States
5 The University of Alabama at Birmingham, Birmingham, Alabama, United States
6 The University of Alabama at Birmingham, Birmingham, Alabama, United States
7 The University of Alabama at Birmingham, Birmingham, Alabama, United States
8 The University of Alabama at Birmingham, Birmingham, Alabama, United States
9 The University of Alabama at Birmingham, Birmingham, Alabama, United States
10 The University of Alabama at Birmingham, Birmingham, Alabama, United States
11 The University of Alabama at Birmingham, Birmingham, Alabama, United States
12 The University of Alabama at Birmingham, Birmingham, Alabama, United States
13 The University of Alabama at Birmingham, Birmingham, Alabama, United States
14 The University of Alabama at Birmingham, Birmingham, Alabama, United States
15 The University of Alabama at Birmingham, Birmingham, Alabama, United States
16 The University of Alabama at Birmingham, Birmingham, Alabama, United States
ABSTRACT
Background
Mid-induction bone marrow (BM) assessment is recommended by NCCN guidelines during acute myeloid leukemia (AML) induction therapy to assess response and the need for re-induction. However, its clinical utility remains uncertain. We prospectively assessed the clinical utility of mid-induction BM assessment in adults with AML receiving intensive induction therapy.
Methods
We conducted a prospective study (NCT06323590) of 60 consecutively enrolled adults with AML treated with 7+3 induction. Mid-induction BM assessment was performed on day 14 (day 21 for FLT3-mutated AML). Per protocol, patients were observed through count recovery without immediate re-induction regardless of BM findings. EOI BM evaluation was performed between days 28 and 42. The primary endpoint was complete remission (CR) rate without treatment modification.
Single-cell CITE-seq was performed on 36 serial BM samples from 13 patients collected before treatment, at mid-induction, and end of induction. Cell populations and differentiation trajectories were analyzed using Cell Ranger and Seurat. Clusters were annotated based on a well-annotated AML reference and differentiation patterns and gene expression profiles were studied. Pathway activities were inferred using PROGENy analysis
Results
Sixty patients were enrolled (median age, 50.5 years [range, 24–69]); 31 (52%) were female and 48 (80%) were White. ELN 2022 risk was favorable in 27 (45%), intermediate in 13 (21%), and adverse in 20 (33%).
Fifty-six patients underwent mid-induction BM evaluation. Four did not because of clinical condition. Forty (71%) had a hypocellular marrow (<20% cellularity), while 16 (29%) had ≥20% cellularity. Overall, 48 patients (86%) had <5% blasts and 8 (14%) had ≥5% blasts. In patients with ≥5% blasts, the median blast percentage was 34% (range, 12–78) and median marrow cellularity was 40% (range, 10–80).
Fifty-five patients underwent EOI BM evaluation; five died before assessment. The CR rate following induction without treatment modification based on mid-induction BM findings was 69%. The CR/CRi rate was 80% (49% MRD negative).
None of the eight patients with ≥5% blasts on mid-induction BM underwent immediate re-induction. Despite morphologic persistence, six patients (75%) achieved CR (4 MRD+, 2 MRD-) without additional induction therapy. One patient with refractory disease received re-induction after day 28 and subsequently achieved remission, while one patient with TP53-mutated AML died before EOI assessment. Patients with <5% blasts on mid-induction BM achieved a CR/CRi rate of 79%. With a median follow-up of 16.2 months, median overall survival was not reached and estimated 12-month overall survival was similar regardless of mid-induction blast clearance (76.4% for <5% blasts vs. 75.0% for ≥5% blasts, p=0.9).
Single-cell CITE-seq analysis revealed heterogeneous pretreatment AML differentiation states, including primitive stem or progenitor (n=9), monocytic (n=2), and intermediate patterns (n=2), without a clear association with remission status. In patients with <5% blasts in mid-induction BM, these AML populations declined with emergence of erythroid progenitors at mid-induction followed by restoration of balanced multilineage differentiation on achievement of remission at EOI (n=9). However, patients with ≥5% blasts at mid-induction (n=4) showed retention of their AML populations with significantly increased expression of hypoxia, JAK-STAT, PI3K, TGFB, VEGF and p53 signaling activity. These AML populations subsequently declined with acquisition of balanced differentiation in 3 patients achieving remission at EOI, whereas expanded AML populations were seen in residual disease at EOI (n=1).
Conclusions
In this prospective cohort of adults with AML receiving intensive induction therapy, routine mid-induction BM assessment had limited ability to identify patients unlikely to achieve remission. Among patients with ≥5% mid-induction blasts, 75% achieved remission without immediate re-induction, suggesting that early morphologic persistence may not represent treatment failure. CITE-Seq analysis suggests that increased blasts in mid-induction samples represent retained leukemia populations that often continue to decline with regeneration of multilineage hematopoiesis without further intervention. These findings question the routine use of mid-induction BM assessment and highlight the need for alternative dynamic biomarkers to guide early response assessment.
DISCLOSURES
Omer Jamy, MD: Ascentage - Consultancy (Includes expert testimony); SELLAS - Consultancy (Includes expert testimony); TERNS - Consultancy (Includes expert testimony)